NMI控股 NMIH 深 沪
等待开盘 12-30 09:30:00 美东时间
41.41
0.000
0.00%
华盛通- 最 高41.545
- 今 开41.53
- 成交量 24.02万股
- 最 低 41.12
- 昨 收 41.41
- 总市值 31.83亿
- 52周最高 43.20
- 市盈率 静 9.35
- 换手率 0.31%
- 52周最低 31.90
- 委 比 -96.91%
- 总股本 7686.79万
- 历史最高 43.20
- 量 比 0.59
- 振 幅 1.03%
- 历史最低 4.19
- 每 手 1
- 风险率 2.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
Keefe, Bruyette & Woods Upgrades NMI Holdings to Outperform, Raises Price Target to $48
Keefe, Bruyette & Woods analyst Bose George upgrades NMI Holdings (NASDAQ:NMIH) from Market Perform to Outperform and raises the price target from $46 to $48.
12-18 17:22
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
JP Morgan Maintains Overweight on NMI Holdings, Lowers Price Target to $42
JP Morgan analyst Richard Shane maintains NMI Holdings (NASDAQ:NMIH) with a Overweight and lowers the price target from $43 to $42.
11-06 04:09
CORRECTION: NMI Holdings Q3 Adj. EPS $1.21, Inline, Sales $178.679M Beat $150.573M Estimate
NMI Holdings (NASDAQ:NMIH) reported quarterly earnings of $1.21 per share which met the analyst consensus estimate. This is a 5.22 percent increase over earnings of $1.15 per share from the same period last year. The
11-05 06:58
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
Barclays Maintains Equal-Weight on NMI Holdings, Raises Price Target to $43
Barclays analyst Terry Ma maintains NMI Holdings (NASDAQ:NMIH) with a Equal-Weight and raises the price target from $42 to $43.
10-06 21:20
NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
NovaBay Pharmaceuticals has entered into a $6 million securities purchase agreement with private investor David E. Lazar, receiving the first closing of $3.85 million. Lazar has been appointed CEO, while former CEO Justin Hall becomes Vice President of Business Development. The transaction prevents NovaBay’s liquidation and allows its shares to continue trading. Proceeds will fund strategic investments or acquisitions, and a special cash dividend...
08-19 21:25
Earnings Scheduled For July 29, 2025
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is projected to repor...
07-29 16:32
